(Q34521684)

2 August 2017

1 reference

title

Intravenous milrinone in cardiac surgery (English)

1 reference

2 August 2017

0 references

1 reference

Jerrold H Levy

1

1 reference

2 August 2017

James M Bailey

series ordinal

2

1 reference

2 August 2017

G Michael Deeb

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

The Annals of Thoracic Surgery

2 August 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 August 2017

73

1 reference

2 August 2017

1

1 reference

2 August 2017

325-330

1 reference

Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

The pharmacokinetics and pharmacodynamics of newer inotropic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. European Multicenter Trial Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Inhibition of vasoconstriction by phosphodiesterase III inhibitor milrinone in human conduit arteries used as coronary bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

A comparative evaluation of the effects of multiple vasodilators on human internal mammary artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Arterial grafts for coronary artery bypass grafting: biological characteristics, functional classification, and clinical choice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

The pharmacokinetics of milrinone in pediatric patients after cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Use of milrinone in cardiac surgical patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Electrophysiology of phosphodiesterase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Electrophysiologic and proarrhythmic effects of intravenous inotropic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Amrinone-associated thrombocytopenia: pharmacokinetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902719-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0003-4975(01)02719-9

1 reference

2 August 2017

1 reference